KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Biomarin Pharmaceutical (BMRN) Return on Equity (2016 - 2025)

Biomarin Pharmaceutical's Return on Equity history spans 16 years, with the latest figure at 0.06% for Q4 2025.

  • For the quarter ending Q4 2025, Return on Equity fell 2.0% year-over-year to 0.06%, compared with a TTM value of 0.06% through Dec 2025, down 2.0%, and an annual FY2025 reading of 0.06%, down 2.0% over the prior year.
  • Return on Equity for Q4 2025 was 0.06% at Biomarin Pharmaceutical, down from 0.09% in the prior quarter.
  • The five-year high for Return on Equity was 0.2% in Q2 2021, with the low at 0.02% in Q4 2021.
  • Average Return on Equity over 5 years is 0.06%, with a median of 0.04% recorded in 2024.
  • Biggest YoY gain for Return on Equity was 16bps in 2021; the steepest drop was -23bps in 2021.
  • Tracing BMRN's Return on Equity over 5 years: stood at 0.02% in 2021, then surged by 305bps to 0.03% in 2022, then increased by 10bps to 0.03% in 2023, then skyrocketed by 126bps to 0.08% in 2024, then dropped by -25bps to 0.06% in 2025.
  • Per Business Quant, the three most recent readings for BMRN's Return on Equity are 0.06% (Q4 2025), 0.09% (Q3 2025), and 0.11% (Q2 2025).